Skip to main content

Originally published March 25, 2014 at 4:21 PM | Page modified March 26, 2014 at 7:01 AM

  • Share:
  • Comments (0)
  • Print

BioLife moving up to Nasdaq’s small-cap market

By Seattle Times staff

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >


BioLife Solutions of Bothell, whose products preserve stored cells, tissues and organs for life-science applications, said it will start trading Wednesday on the Nasdaq Capital Market, NASDAQ’s market for small-cap companies.

The company, previously traded over the counter, said in a regulatory filing it has completed the sale of $15.4 million in stock and warrants and erased $14.3 million in debt by converting it to equity on similar terms.

BioLife last month reported 2013 sales of $8.5 million, up 58 percent from the prior year, and a net loss of $1.1 million, down from $1.7 million.

The company said it will retain its current ticker symbol, BLFS. The securities sale and debt-to-equity conversion increased BioLife’s outstanding shares to 12 million, according to president and CEO Mike Rice, yielding a market capitalization of nearly $50 million at Tuesday’s closing price of $3.85.

Free 4-week trial, then $99 a year for unlimited access. Try it now!

News where, when and how you want it

Email Icon

Free 4-week trial, then $99 a year.

Free 4-week trial, then $99 a year.

Unlimited access. Try it now.



The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited content access is included with most subscriptions.

Subscriber login ►